Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

Lignende værker

• Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
  af: Roboz, Gail J, et al.
  Udgivet: (2016)
• Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
  af: Garcia-Manero, Guillermo, et al.
  Udgivet: (2021)
• Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
  af: Garcia-Manero, G, et al.
  Udgivet: (2016)
• Current treatment algorithm for the management of lower-risk MDS
  af: Giagounidis, Aristoteles
  Udgivet: (2017)
• Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
  af: Savona, Michael R., et al.
  Udgivet: (2018)